Please try another search
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Timothy M. Block | 69 | 2013 | Independent Director |
Philippe Gallay | - | 2016 | Member of Scientific Advisory Board |
John Patrick Brancaccio | 76 | 2013 | Independent Chairman |
Nikolai V. Naoumov | - | 2023 | Member of Scientific Advisory Board |
Kaouthar Lbiati | 45 | 2022 | Independent Director |
Rohit Loomba | - | 2023 | Member of Scientific Advisory Board |
Yury V. Popov | - | 2023 | Member of Scientific Advisory Board |
Vlad Raziu | - | 2023 | Member of Scientific Advisory Board |
Stephen A. Harrison | - | 2019 | Scientific Advisory Board Chair & Consultant Medical Director |
Michael J. Purcell | 66 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review